tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- Am. J. Physiol. Renal Physiol. (1)
- Drug Metab. Dispos. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| The discovery of FK-506 and U.S. development. | 1991 | Nephrol News Issues | pmid:1720512 | |
| Zheng B et al. | Effects of the new and highly active immunosuppressant, rapamycin, on lymphoid tissues and cells in vivo. | 1991 | Transplant. Proc. | pmid:1703717 |
| Mieles L et al. | Interaction between FK506 and clotrimazole in a liver transplant recipient. | 1991 | Transplantation | pmid:1721250 |
| Yabuuchi H et al. | Prominent prolongation of islet xenograft survival in combination therapy with FK 506 and 15-deoxyspergualin. | 1991 | Transplant. Proc. | pmid:1703718 |
| First International Congress on FK 506. August 21-24, 1991, Pittsburgh, PA. | 1991 | Transplant. Proc. | pmid:1721253 | |
| Goto T et al. | FK 506: historical perspectives. | 1991 | Transplant. Proc. | pmid:1721254 |
| Ochiai T et al. | Effective and safe use of FK 506: combination treatment with rapamycin or RS-61443 in experimental organ transplantation. | 1991 | Transplant. Proc. | pmid:1721255 |
| Siekierka JJ et al. | Potential roles of other FK 506-binding proteins in mediating the effects of FK 506. | 1991 | Transplant. Proc. | pmid:1721256 |
| Morris RE | In vivo immunopharmacology of the macrolides FK 506 and rapamycin: toward the era of rational immunosuppressive drug discovery, development, and use. | 1991 | Transplant. Proc. | pmid:1721257 |
| Kobayashi M et al. | FK 506 assay past and present--characteristics of FK 506 ELISA. | 1991 | Transplant. Proc. | pmid:1721258 |
| Farghali H et al. | Effect of FK 506 chronic administration on bromosulphthalein hepatic excretion in rats. | 1991 | Transplant. Proc. | pmid:1721283 |
| Farghali H et al. | A biochemical and 31P-NMR investigation of the effect of FK 506 and cyclosporine pretreatment on immobilized hepatocytes perifused with ethanol. | 1991 | Transplant. Proc. | pmid:1721284 |
| Farghali H et al. | FK 506 modulates D-galactosamine-induced hepatitis in rats. | 1991 | Transplant. Proc. | pmid:1721285 |
| Müller MK et al. | Inhibition of insulin release by FK 506 and its prevention by rioprostil, a stable prostaglandin E1 analogue. | 1991 | Transplant. Proc. | pmid:1721286 |
| Francavilla A et al. | The effects of FK 506, cyclosporine, and rapamycin on liver growth in vitro and in vivo. | 1991 | Transplant. Proc. | pmid:1721287 |
| Blanc P et al. | Antiproliferative effect of FK 506 and cyclosporine on adult human hepatocytes in culture. | 1991 | Transplant. Proc. | pmid:1721288 |
| Loréal O et al. | FK 506 is less cytotoxic than cyclosporine to human and rat hepatocytes in vitro. | 1991 | Transplant. Proc. | pmid:1721289 |
| McCauley J et al. | Cyclosporine and FK 506 induced inhibition of renal epithelial cell proliferation. | 1991 | Transplant. Proc. | pmid:1721290 |
| McLachlan G et al. | Growth inhibition of the MOLT-4 human T-leukemia cell line. A comparison of cyclosporine and FK 506. | 1991 | Transplant. Proc. | pmid:1721291 |
| Zeevi A et al. | Comparative in vitro studies on the immunosuppressive activities of mycophenolic acid, bredinin, FK 506, cyclosporine, and rapamycin. | 1991 | Transplant. Proc. | pmid:1721315 |
| Matsuura T et al. | Beneficial immunosuppressive effect of combined use of FK 506 and cyclosporine assessed by proliferative responses of cloned human T cells. | 1991 | Transplant. Proc. | pmid:1721316 |
| Jiang H et al. | Combined immunosuppressive effect of FK 506 and other immunosuppressive agents on PHA- and CD3-stimulated human lymphocyte proliferation in vitro. | 1991 | Transplant. Proc. | pmid:1721317 |
| Yagihashi A et al. | The effect of FK 506 on peripheral blood T-lymphocyte subsets in orthotopic liver transplant patients. | 1991 | Transplant. Proc. | pmid:1721318 |
| Woo J et al. | Effects of FK 506, mycophenolic acid, and bredinin on OKT-3-, PMA-, and alloantigen-induced activation molecule expression on cultured CD4+ and CD8+ human lymphocytes. | 1991 | Transplant. Proc. | pmid:1721319 |
| Chen-Woan M et al. | Diminished lymphocyte growth from endomyocardial biopsies from cardiac transplant patients on FK 506 immunosuppression. | 1991 | Transplant. Proc. | pmid:1721320 |
| Fukuzawa M et al. | Effect of FK 506 on CD4+ and CD8+ T-cell function in vivo. | 1991 | Transplant. Proc. | pmid:1721321 |
| Takaori K et al. | Effects of FK 506 on in vivo immunity in comparison to cyclosporine. | 1991 | Transplant. Proc. | pmid:1721322 |
| Jain AB et al. | Correlation of rejection episodes with FK 506 dosage, FK 506 level, and steroids following primary orthotopic liver transplant. | 1991 | Transplant. Proc. | pmid:1721347 |
| Takaya S et al. | Retransplantation of liver: a comparison of FK 506- and cyclosporine-treated patients. | 1991 | Transplant. Proc. | pmid:1721348 |
| Morel P et al. | Liver retransplantation in adults: overall results and determinant factors affecting the outcome. | 1991 | Transplant. Proc. | pmid:1721349 |
| Felser I et al. | Changes in quality of life following conversion from CyA to FK 506 in orthotopic liver transplant patients. | 1991 | Transplant. Proc. | pmid:1721350 |
| Schreiber SL | Chemistry and biology of the immunophilins and their immunosuppressive ligands. | 1991 | Science | pmid:1702904 |
| Alessiani M et al. | CMV infection in liver transplantation under cyclosporine or FK 506 immunosuppression. | 1991 | Transplant. Proc. | pmid:1721351 |
| Wasik M et al. | Effect of FK506 versus cyclosporine on human natural and antibody-dependent cytotoxicity reactions in vitro. | 1991 | Transplantation | pmid:1702910 |
| Green M et al. | Infectious complications of pediatric liver transplantation under FK 506. | 1991 | Transplant. Proc. | pmid:1721352 |
| Carroll PB et al. | Effect of the immunosuppressant FK506 on glucose-induced insulin secretion from adult rat islets of Langerhans. | 1991 | Transplantation | pmid:1702911 |
| Torre-Cisneros J et al. | The spectrum of aspergillosis in liver transplant patients: comparison of FK 506 and cyclosporine immunosuppression. | 1991 | Transplant. Proc. | pmid:1721353 |
| Starzl TE et al. | Hepatotrophic effects of FK506 in dogs. | 1991 | Transplantation | pmid:1702912 |
| Paul AA et al. | CMV retinitis and the use of FK 506. | 1991 | Transplant. Proc. | pmid:1721354 |
| Keicho N et al. | Effects of an immunosuppressant, FK506, on interleukin 1 alpha production by human macrophages and a macrophage-like cell line, U937. | 1991 | Cell. Immunol. | pmid:1703047 |
| Prasad SJ et al. | In vitro effects of cyclosporine and FK 506 on the renal cortex. | 1991 | Transplant. Proc. | pmid:1721380 |
| Kusne S et al. | Early infections in kidney transplant recipients under FK 506. | 1991 | Transplant. Proc. | pmid:1703364 |
| Yamada K et al. | Short-term FK 506-induced morphological changes in rat kidneys. | 1991 | Transplant. Proc. | pmid:1721381 |
| Moutabarrik A et al. | FK 506 mechanism of nephrotoxicity: stimulatory effect on endothelin secretion by cultured kidney cells and tubular cell toxicity in vitro. | 1991 | Transplant. Proc. | pmid:1721382 |
| Moutabarrik A et al. | In vitro FK 506 kidney tubular cell toxicity. | 1991 | Transplant. Proc. | pmid:1721383 |
| McCauley J et al. | Changes in renal function after liver transplantation under FK 506. | 1991 | Transplant. Proc. | pmid:1721385 |
| Tauxe WN et al. | A comparison of the renal effects (ERPF, GFR, and FF) of FK 506 and cyclosporine in patients with liver transplantation. | 1991 | Transplant. Proc. | pmid:1721386 |
| McCauley J et al. | Renal function after conversion from cyclosporine to FK 506 in liver transplant patients. | 1991 | Transplant. Proc. | pmid:1721387 |
| Ricordi C et al. | Human islet allotransplantation under FK 506. | 1991 | Transplant. Proc. | pmid:1721410 |
| Tze WJ et al. | Long-term survival of islet allografts in diabetic rats treated with FK 506. | 1991 | Transplant. Proc. | pmid:1721411 |
| Wang X et al. | Intraportal FK 506 improves intrahepatic islet allograft survival. | 1991 | Transplant. Proc. | pmid:1721412 |
| Ohtsuka S et al. | The effect of short-term FK 506 therapy on pancreas transplantation in rats. | 1991 | Transplant. Proc. | pmid:1721413 |
| Yamashita T et al. | Prolongation of pancreaticoduodenal allograft survival in rats by treatment with FK 506. | 1991 | Transplant. Proc. | pmid:1721414 |
| Fukuzaki T et al. | Induction of tolerance to islet allografts with preoperative donor spleen cell injection and a short course of FK 506 treatment. | 1991 | Transplant. Proc. | pmid:1721415 |
| Tzakis AG et al. | FK 506 rescue in chronic graft-versus-host-disease after bone marrow transplantation. | 1991 | Transplant. Proc. | pmid:1721416 |
| Masaoka T et al. | Phase II study of FK 506 for allogeneic bone marrow transplantation. | 1991 | Transplant. Proc. | pmid:1721417 |
| Brabletz T et al. | The immunosuppressives FK 506 and cyclosporin A inhibit the generation of protein factors binding to the two purine boxes of the interleukin 2 enhancer. | 1991 | Nucleic Acids Res. | pmid:1707162 |
| Iwaki Y et al. | Replacement of donor lymphoid tissue in small-bowel transplants. | 1991 | Lancet | pmid:1707470 |
| Markus PM et al. | Effects of in vivo treatment with FK506 on natural killer cells in rats. | 1991 | Transplantation | pmid:1707562 |
| Lin CS et al. | FK-506 and cyclosporin A inhibit highly similar signal transduction pathways in human T lymphocytes. | 1991 | Cell. Immunol. | pmid:1707760 |
| Vincent SH et al. | Effects of the immunosuppressant FK-506 and its analog FK-520 on hepatic and renal cytochrome P450 mixed-function oxidase. | 1991 | Biochem. Pharmacol. | pmid:1708254 |
| Kitahara S et al. | Lymphoproliferative disorders after FK 506. | 1991 | Lancet | pmid:1708846 |
| Holechek MJ | Medication review: FK 506. | 1991 | ANNA J | pmid:1708982 |
| Yokomise H et al. | Immunosuppressive effects of FK 506 in canine lung transplantation. | 1991 | Transplant. Proc. | pmid:1721442 |
| Hasegawa S et al. | FK 506 and cyclosporine: effects and side effects in canine lung transplantation. | 1991 | Transplant. Proc. | pmid:1721443 |
| Wada H et al. | Dose response to FK 506 in canine lung transplantation. | 1991 | Transplant. Proc. | pmid:1721444 |
| Lin CY et al. | Effects of FK 506 on the biochemical markers in canine lung allograft rejection. | 1991 | Transplant. Proc. | pmid:1721445 |
| Propper DJ et al. | Evidence that FK 506 may abrogate suppressor cell activity induced by blood transfusion. | 1991 | Transplant. Proc. | pmid:1721446 |
| Fabrega AJ et al. | FK 506 enhances the beneficial effects of donor-specific blood transfusion on allograft survival in rats. | 1991 | Transplant. Proc. | pmid:1721447 |
| Davies CB et al. | Effects of donor-specific transfusion, cyclosporine A and FK 506 on rat cardiac allograft survival. | 1991 | Transplant. Proc. | pmid:1721448 |
| Abu-Elmagd K et al. | FK 506: a new therapeutic agent for severe recalcitrant psoriasis. | 1991 | Transplant. Proc. | pmid:1721449 |
| Banerji SS et al. | The immunosuppressant FK-506 specifically inhibits mitogen-induced activation of the interleukin-2 promoter and the isolated enhancer elements NFIL-2A and NF-AT1. | 1991 | Mol. Cell. Biol. | pmid:1712901 |
| Markus PM et al. | FK 506 reverses acute graft-versus-host disease after allogeneic bone marrow transplantation in rats. | 1991 | Surgery | pmid:1713358 |
| Farley DE et al. | The effect of two new immunosuppressive agents, FK506 and didemnin B, in murine pregnancy. | 1991 | Transplantation | pmid:1713360 |
| Vathsala A et al. | The immunosuppressive antagonism of low doses of FK506 and cyclosporine. | 1991 | Transplantation | pmid:1713361 |
| Kawano K et al. | A protective effect of FK506 in ischemically injured rat livers. | 1991 | Transplantation | pmid:1713362 |
| Armitage JM et al. | Preliminary experience with FK506 in thoracic transplantation. | 1991 | Transplantation | pmid:1713363 |
| Lorber MI et al. | A comparison of in vivo responses to cyclosporine, FK506, and rapamycin following allogeneic immune challenge. | 1991 | Transplantation | pmid:1713364 |
| Abu-Elmagd K et al. | The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver. | 1991 | Transplantation | pmid:1713365 |
| Takada K et al. | Pharmacokinetics of FK-506, a novel immunosuppressant, after intravenous and oral administrations to rats. | 1991 | J. Pharmacobio-dyn. | pmid:1713626 |
| Sakai K et al. | The effect of a new immunosuppressive agent, FK-506, on xenogeneic neural transplantation in rodents. | 1991 | Brain Res. | pmid:1723023 |
| Weaver JL et al. | Comparison of the in vitro and biophysical effects of cyclosporine A, FK-506, and mycophenolic acid on human peripheral blood lymphocytes. | 1991 | Immunopharmacol Immunotoxicol | pmid:1723084 |
| DiLella AG and Craig RJ | Exon organization of the human FKBP-12 gene: correlation with structural and functional protein domains. | 1991 | Biochemistry | pmid:1716149 |
| Burres NS et al. | Dunaimycins, a new complex of spiroketal 24-membered macrolides with immunosuppressive activity. III. Immunosuppressive activities of dunaimycins. | 1991 | J. Antibiot. | pmid:1723403 |
| Nielsen JB et al. | Biosynthesis of the immunosuppressant immunomycin: the enzymology of pipecolate incorporation. | 1991 | Biochemistry | pmid:2043618 |
| McKeon F | When worlds collide: immunosuppressants meet protein phosphatases. | 1991 | Cell | pmid:1716181 |
| Petros AM et al. | NMR studies of an FK-506 analogue, [U-13C]ascomycin, bound to FKBP: conformation and regions of ascomycin involved in binding. | 1991 | J. Med. Chem. | pmid:1716684 |
| FK 506--an investigational immunosuppressant. | 1991 | Med Lett Drugs Ther | pmid:1716722 | |
| Ochiai T et al. | [Immunosuppressive agents--advances of the developmental studies and the mode of action]. | 1991 | Nippon Rinsho | pmid:1715926 |
| Ricordi C et al. | In vivo effect of FK506 on human pancreatic islets. | 1991 | Transplantation | pmid:1716797 |
| Katz IA et al. | Comparison of the effects of FK506 and cyclosporine on bone mineral metabolism in the rat. A pilot study. | 1991 | Transplantation | pmid:1716801 |
| Jiang H et al. | Effect of FK-506 on heart allograft survival in the highly sensitized recipient rats as compared with ciclosporin and 15-deoxyspergualin. | 1991 | Eur Surg Res | pmid:1723683 |
| Pezze JL and Whiteman K | Transplantation's newest weapon FK 506. | 1991 | Am J Nurs | pmid:1716857 |
| Romanowski P et al. | [Synthetic immunomodulators designed on the basis of natural products of microorganisms]. | 1991 | Postepy Biochem. | pmid:1725924 |
| Altmeyer A et al. | Unexpected up-regulation of gene expression by cyclosporin A and FK-506 in a T-cell lymphoma: both immunosuppressants augment Ly-6E antigen induction by interferon-gamma in the presence of ionomycin. | 1991 | Int. J. Immunopharmacol. | pmid:1726093 |
| Gordon RD et al. | Liver transplantation at the University of Pittsburgh, 1984 to 1990. | 1991 | Clin Transpl | pmid:1726458 |
| Jamieson NV et al. | Orthotopic liver transplantation at Addenbrooke's Hospital Cambridge 1968 to 1991. | 1991 | Clin Transpl | pmid:1726459 |
| Takahara S et al. | Survival of cardiac allograft in highly sensitized and nonsensitized rats treated with FK506. | 1991 | J Clin Lab Immunol | pmid:1726566 |
| Stötter H and Lotze MT | Human lymphokine-activated killer cell activity. Role of IL-2, IL-4, and IL-7. | 1991 | Arch Surg | pmid:1726819 |
| Karlsson H and Nässberger L | FK506 lacks the ability to inhibit expression of interleukin-2 receptor beta-chain on human lymphocytes. | 1991 | J Clin Lab Immunol | pmid:1726895 |